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The Role of TDP-43 in 
Genome Repair and beyond in 
Amyotrophic Lateral Sclerosis
Joy Mitra and Muralidhar L. Hegde
Abstract
The pathology of the RNA-/DNA-binding protein TDP-43, first implicated a 
decade ago in the motor neuron disease amyotrophic lateral sclerosis (ALS), has 
been subsequently linked to a wide spectrum of neurodegenerative diseases, includ-
ing frontotemporal dementia (FTD), Alzheimer’s disease (AD), and related demen-
tia-associated disorders. ALS, also known as Lou Gehrig’s disease, is a progressive, 
degenerative motor neuron disorder, characterized by a diverse etiopathology. TDP-
43 pathology, mediated by a combination of several mutations in the TARDBP gene 
and stress factors, has been linked to more than 97% of ALS patients. We recently 
identified, for the first time, the critical involvement of TDP-43 in neuronal genome 
maintenance and the repair of DNA double-strand breaks (DSBs). Our studies 
showed that TDP-43 regulates the DNA break-sealing activities of the XRCC4-DNA 
Ligase 4 (LIG4) complex in DSB repair, suggesting that loss of genomic integrity 
in TDP-43-associated neurodegeneration may be amenable to a DNA repair-based 
intervention. In this chapter, we discuss the broader aspects of TDP-43 toxicity-
induced pathomechanisms, including the emerging role of TDP-43 in neuronal DSB 
repair and its synergistic genotoxic effects with other neurodegeneration-associated 
etiologies that contribute significantly to neuronal dysfunction. We also discuss 
potential future perspectives and underscore how unraveling the molecular basis 
and implications of TDP-43-induced genome instability in ALS could guide the 
development of neuroprotective therapies.
Keywords: TDP-43, DNA damage, DNA double-strand breaks, nonhomologous end 
joining, XRCC4-DNA ligase 4, ALS, stress granule, Rab11, neurodegeneration
1. TDP-43 pathology: a predominant player in ALS
Transactive response DNA-binding protein 43 (TDP-43) is a versatile 43 kDa 
DNA-/RNA-binding protein of the heterogeneous nuclear ribonucleoprotein 
(hnRNP) family. TDP-43’s cytosolic aggregation and inclusion body formation 
are the key pathologic hallmarks of amyotrophic lateral sclerosis (ALS) and fron-
totemporal dementia (FTD) [1–3]. In these progressive motor neuron diseases, 
TDP-43 pathology manifests as the tau- and synuclein- negative and ubiquitin-
positive inclusions in the anterior horn, spinal cord, neocortex, and hippocampus 
regions of the brain. In the last decade, tremendous scientific investigations have 
been carried out to understand the etiopathologies of TDP-43 toxicity in ALS and 
FTD. These studies demonstrated that TDP-43 pathology-linked ALS is one of the 
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most complex neurological diseases due to TDP-43 pathomechanisms overlapping 
with other ALS-causing genes, such as C9orf72 [4–6], valosin-containing protein 
(VCP) [7–9], fused in sarcoma (FUS) [10], optineurin (OPTN) [11], ubiquilin 2 
(UBQLN2) [12, 13], and ataxin 2 (ATXN2) [14, 15]. Strikingly, TDP-43 pathology 
has been detected in more than 97% of sporadic ALS cases (>90%), making it a 
predominant player in most ALS patients.
1.1 Familial and sporadic ALS
Due to highly overlapping symptoms, determining the sporadic or familial 
nature of the ALS disease at its time of onset is difficult based on clinical fea-
tures alone. Familial ALS (FALS) is predicted based on genetic screening for 
TARDBP mutation(s) in the patient and matching the same mutation in the family 
member(s) with a positive clinical/medical history of neurodegeneration and 
dementia in the juvenile or early stage of life. Race, age, and gender are risk factors 
for progression of FALS. FALS incidences vary significantly from 5 to 10% among 
all ALS cases. The disease is more common in Caucasian men and women than 
African, Asian, and Hispanic populations [16]. Notably, clusters of ALS incidences 
have been associated with socio-economic conditions along with race. According 
to Centers for Disease Control and Prevention, ALS prevalence is highest in the 
Midwest and Northeast of US main land (5.7 and 5.5 per 100,000 population, 
respectively) [17]. In Europe, the prevalence of FALS was lower in the southern part 
[18]. Studies show that men are at slightly higher risk than women, with an aver-
age age of onset ~60 years. Patients usually survive for 1.5–4 years after diagnosis, 
depending on the disease aggressiveness [19].
FALS associated pathology affects anterior horn motor neurons in the cervical 
and lumbosacral regions in the spinal cord, frontal cortex, and cranial nerve motor 
neurons in the pons and medulla segments of brainstem. Both sporadic ALS (SALS) 
and FALS pathologies are associated with upper and/or lower motor neurons of the 
spinal cord. Upper motor neuron diseases accompany degeneration of lateral cor-
ticospinal tracts leading to hyperreflexia/spasticity and cardiac arrest. Conversely, 
lower motor neuron death leads to muscle atrophy and denervation.
FALS cases fall into to three categories, namely, autosomal dominant, autosomal 
recessive, and X-linked dominant. Autosomal dominance is the most common inher-
ited pattern among the FALS cases, where a mutation in one copy of the ALS-linked 
gene is sufficient to develop ALS conditions. These patients usually have a strong 
positive family history and their children bear 50% risk of developing ALS. However, 
autosomal dominance can also happen in apparently sporadic ALS (because the 
genetic inheritance is unknown or poor medical history) with de novo dominant 
mutation(s). In such cases, patients’ siblings may have very low risk but children may 
have up to 50% risk of developing ALS. To date, more than 50 mutations in TARDBP 
gene have been identified in ALS etiopathologies [20]. In addition, a study on a 
German cohort of non-SOD1 FALS patients revealed mutations in TARDBP, sug-
gesting TARDBP gene mutation screening should be crucial among non-SOD1 FALS 
patients [21]. The known TARDBP mutations in FALS are G290A, G298S, A315T, 
M337V, N345K, A382T, and I383V; some of the common mutations identified in SALS 
are D169G, G287S, G294A, Q331K, G348C, R361S, and N390S/D (Figure 1) [21–27]. 
Most of these TARDBP mutations are located within exon 6, as commonly found 
in Caucasian and European ALS patients; however, a large cohort of Han Chinese 
population with non-SOD1 SALS did not show any such mutations in exon 6 [28].
SALS has been reported in an increasing number among people exposed to lead 
or other heavy metals [29–31], smoking [32, 33], and pesticides [34]. Increased 
exposure to organochlorine pesticides, biphenyls, and brominated flame retardants 
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used in household furniture is associated with higher risk for ALS [35–37]. 
Interestingly, while smoking has been shown to predispose individuals to ALS 
risk, alcohol consumption did not show any effect on ALS development [38]. This 
suggests that diet and exposure to various environmental toxins could increase the 
ALS susceptibility in the vulnerable population. Most notably, US veterans from the 
Gulf War [39, 40] and those with head injury [41, 42] are also at a greater risk for 
developing SALS. By targeted sequencing of exon 6 of TARDBP from brain samples 
of US veterans with SALS, we observed several missense mutations (both reported 
and novel) and the association of TDP-43 Q331K mutation with DNA DSB repair 
impairment [22]. Another well-known incidence of sporadic ALS is the Guamanian 
ALS, which falls on the Parkinsonism-dementia complex spectrum (ALS/PDC). 
This particular type of ALS in people living in Guam and Rota islands is caused by 
the consumption of cyanobacteria-infested cycad fruits containing the neurotoxin 
β-methylamino-L-alanine (BMAA) [43, 44]. BMAA exerts neurotoxicity by incor-
porating into amino acid sequences and inducing tau pathology, oxidative stress, 
glutathione depletion, and protein aggregation [45–48]. Genome-wide analyses for 
ALS-/PDC-associated chromosomal loci revealed three disease-specific loci—two 
regions on chromosome 12 and the MAPT region on chromosome 17—in these 
populations [49].
1.2  Unique feature of TDP-43 pathology: dual role of loss of function  
and gain of toxicity
Given that TDP-43 contains a prion-like domain, its cellular content and distri-
bution are two contributing factors for preventing the protein aggregation leading 
to the onset of disease. These two conditions are maintained by TDP-43’s autoregu-
latory feedback loop mechanism. TDP-43 is mainly a nuclear protein, but it also 
shuttles to the cytosol, mitochondria, and other cellular organelles in response to 
various stimuli. In ALS/FTD pathology, TDP-43 mislocalization, due to pathogenic 
mutations and/or protein aggregation, is known as the primary culprit for the onset 
of neurodegeneration. Studies suggest that initiation of caspase-3/7 activation by 
TDP-43 toxicity facilitates the disease progression by cleaving mislocalized TDP-43 
into 35 and 25 kDa fragments. These highly aggregation-prone fragments promote 
inclusion body formations with the hyperphosphorylated and polyubiquitinated 
C-terminal domain of TDP-43 [50, 51]. In addition to the C-terminal fragment, 
full-length and homo-dimerized TDP-43 also has been identified in the spinal cord 
Figure 1. 
TDP-43 protein’s structural organization. Schematic representation of TDP-43 protein structure shows 
N-terminal domain of TDP-43 consists of highly ordered nucleic acid binding domains, namely, RNA 
recognition motifs (RRM) 1 and 2. RRM1 domain follows a bifurcated nuclear localization signal sequence 
(82–98aa)—NLS1 and NLS2. RRM1 domain spans from 104 to 176aa. RRM2 domain ranges from 192aa to 
262aa including bifurcated nuclear export signal sequence (239–250aa)—NES1 and NES2. Later part in the 
C-terminal domain is mostly disordered and contains majority of the pathogenic mutational hotspots. Familial 
ALS-related mutations are indicated in red, and sporadic ALS-linked mutations are in blue color.
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and brain of ALS patients [52, 53]. Furthermore, recent findings have highlighted 
that this protein aggregation enhances the aggregation propensities of other 
prion-like domain containing proteins. The interaction of these prion-like proteins 
increasing the disease complexity severalfold higher than that of single-protein 
toxicities [54]. TDP-43’s cellular shuttling is regulated by the bifurcated nuclear 
localization signal (NLS) and nuclear export signal (NES) sequences (Figure 1), 
and loss of either of these signal sequences could be deleterious for cell survival. 
In vitro studies expressing NLS-deleted TDP-43 found accelerated cytoplasmic 
aggregate formation along with aberrant RNA processing defects [55, 56]. This phe-
nomenon was further supported by in vivo studies with a transgenic mouse model 
and transcriptomic analysis in ALS/FTD human brain samples, which revealed 
significantly altered mRNA splicing of histones and aberrant chromatin remod-
eling following cytosolic accumulation of toxic TDP-43 [57]. Almost all of the 
pathogenic sporadic and familial mutations in TDP-43 induce its nuclear clearance 
and cytosolic sequestration to varying extents. However, in vitro studies with the 
FALS-linked, NLS-specific A90V mutation in TDP-43 found disease-like detergent 
insoluble cytosolic aggregates, confirming the crucial role of NLS/NES sequences in 
TDP-43 homeostasis, and further suggesting cytosolic aggregation of TDP-43 is a 
determining factor in motor neuron death [58, 59].
Persistent neuroinflammation is considered one of the leading causes for motor 
neuron death in ALS/FTD and also affects patients’ therapeutic response. Innate 
immune responses, including microglial hyperactivation and astrogliosis, were 
consistently documented in human postmortem ALS human brain and spinal 
cord, as well as brains from ALS-model mice [60–63]. TDP-43 plays a vital role in 
regulation of neuroinflammation by inhibiting NF-κB activation, possibly through 
competitive binding to importin α3 [64]. TDP-43 depletion or nuclear loss induces 
extracellular secretion of TNF-α and enhanced nuclear localization of NF-κB p65 in 
glia and neurons [65–67]. Furthermore, inflammatory responses increase nuclear 
loss of TDP-43 and progression of ALS/FTD pathology.
2. Broad functions of TDP-43 in central nervous system (CNS)
2.1 RNA transactions
Extensive research in the last decade on TDP-43 toxicity in ALS has established 
that TDP-43 has multiple functions, including autoregulation of its levels through 
a negative feedback loop and controlling a diverse set of RNA-associated mecha-
nisms, including pre-mRNA processing and splicing, micro RNA biogenesis, and 
RNA transport, transcription, and translation. Importantly, TDP-43 also regulates 
protein levels of critical RNA-binding proteins involved in RNA splicing, including 
SRSF1, PTB, and hnRNP L [68, 69]. TDP-43’s autoregulation is solely controlled 
by the TDP-43-binding region (TDPBR) domain, which is comprised of several 
polyadenylation (pA) sites. The silent intron-7 linked to the TDPBR regulates the 
alternative splicing of pA sites based on the TDP-43 cellular concentration. In the 
steady state, pA1 allows cytoplasmic shuttling of TDP-43 mRNA for the appropriate 
amount of protein production. When overexpressed, TDP-43 binds threefold more 
to TDPBR and increases polymerase II binding at this sequence, which then pro-
cesses intron-7 to remove the pA1 signal sequence and enforces the use of pA2 and 
pA4 sites [70]. The use of pA2/A4 sites makes the TDP-43 mRNA partially retained 
in the nucleus and leads to reduced production of TDP-43 protein in the cell [71]. 
Moreover, a recent study on TDP-43 autoregulation using the Drosophila model 
has identified human homolog transcription elongation regulator 1 (TCGER1) of 
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Drosophila protein GC42724 as having a role in TDP-43 mRNA alternative splicing 
and nucleo-cytoplasmic shuttling. TCGER1 regulates TDP-43 production through 
its TDPBR region [72].
TDP-43 contains two RNA recognition motifs (RRMs): RRM1 and RRM2 
(Figure 1). Each RRM contains two highly conserved RNA recognition segments: 
octameric ribonucleoprotein 1 and hexameric ribonucleoprotein 2 [73]. TDP-43 
RRMs bind a minimum of six UG/TG repeats, and its binding affinity increases 
with increasing numbers of repeats [74]. However, the binding preference is quite 
different between two motifs; unlike RRM1, RRM2 prefers a short stretch of UG 
repeats over long repeats ((UG)3 > (UG)6) [75].
Amino acid sequence analysis reveals a high degree of sequence similarities in 
the N-terminal domains of TDP-43 among human, mouse, rat, Drosophila melano-
gaster, and Caenorhabditis elegans, suggesting that TDP-43’s function is crucial in 
these organisms. The C-terminal region of TDP-43 is predominantly disordered in 
its native structure, comprising a prion-like domain and several glycine-asparagine 
rich patches that contribute to the exon-skipping activity of TDP-43 (Figure 1). 
In vivo studies have revealed that TDP-43 regulates its splicing mechanism via 
its C-terminal glycine-rich domains [76]. A recent study of TDP-43 knockdown 
in a Drosophila model expressing chimeric repressor proteins demonstrated that 
TDP-43 in motor neurons regulates RNA splicing fidelity through splicing repres-
sion [77]. These findings are in agreement with previous studies reporting TDP-43’s 
interaction with more than 6000 mRNAs in the mouse brain and TDP-43 depletion-
induced altered splicing of ~900 mRNAs causing neuronal vulnerability (Figure 2) 
[78]. Furthermore, a recent study with ALS-TDP-43 M337V mutant knock-in 
mouse model has revealed mRNA splicing deregulation as the major pathological 
hallmark of mutant TDP-43, even in the absence of any noticeable motor deficits 
[79]. The mammalian TDP-43 primary transcript produces 11 alternatively spliced 
variants of mRNA, further supporting the functional complexity of TDP-43 
[80]. As part of the hnRNP family, TDP-43 has a similar domain organization to 
hnRNP A1 and A2/B1 [81]. TDP-43’s C-terminal domain interacts with a number of 
hnRNP family proteins, particularly hnRNP A2/B1 and A1, to form the hnRNP rich 
complex that is crucial for splicing inhibition [82]. HnRNP A1, a 34 kDa protein, 
is abundant in motor neurons and has been implicated in the pathomechanism of 
spino-muscular atrophy [83]. Mislocalized TDP-43 modulates the inclusion of exon 
7B in the alternatively spliced hnRNP A1 transcript, leading to the production of an 
isoform with an extended prion-like domain [84–86]. Because TDP-43 and hnRNP 
A1 interact directly, increasing the aggregation propensity of hnRNP A1 could 
strongly influence TDP-43’s aggregation in a synergistic pattern [87].
In addition to pre-mRNA splicing regulation, the N-terminal domain (NTD) of 
TDP-43 plays an essential role in protein stabilization and prevention of pathogenic 
cytoplasmic aggregation. In vitro studies have shown that N-terminal Leu71 and 
Val72 in the β7 strand region at the interface are crucial for its homodimeriza-
tion into dimers and/or tetramers in a concentration-dependent manner [88]. 
Furthermore, single amino acid substitutions at V31R and T32R disrupt TDP-43’s 
splicing activity and induce aggregation. The L28A mutation strongly destabilizes 
the TDP-43 NTD and promotes its mislocalization, and the L27A mutation increases 
its monomeric forms [89]. Recent findings by Chen et al. show that the K181E 
mutation near the TDP-43 RRM1 domain disrupts TDP-43’s ability to process 
mRNA, induces mutant TDP-43 hyperphosphorylation, enhances detergent-resis-
tant aggregation propensity by several fold, and leads to more wild-type TDP-43 in 
the nuclear and cytoplasmic inclusion bodies [90]. TDP-43 oligomerization has 
been reported to be the first toxic intermediate in TDP-43 proteinopathies [91]. An 
RNA-mediated intervention strategy showed inhibition of TDP-43 misfolding in 
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wild-type and pathogenic ALS-TDP-43 mutants, further suggesting a critical role 
for RRM domains in TDP-43 pathology.
MicroRNAs (miRNAs) are the master regulators of a number of vital cellular 
mechanisms and diseases, including neurodegeneration and genomic instability. 
TDP-43 regulates a subset of miRNAs by direct interaction and modulates their 
biogenesis through Drosha and Dicer complexes [92]. In the brain, neurexin-1 
(NRXN1) controls vesicular trafficking between synaptic junctions. TDP-43 has 
been shown to bind mir-NID1 to suppress NRXN1 expression and thereby inhibit 
neuronal development and functionality [93]. Given that long noncoding RNA 
(lncRNA) confers a higher degree of gene expression regulation, TDP-43’s increased 
interaction with two crucial lncRNAs, MALAT1 and NEAT1, possibly modulates 
the RNA metabolism dysregulation of ALS- and FTD-associated TDP-43 pathology 
[94, 95]. Furthermore, lncRNA gadd7, which is involved in cell cycle regulation and 
DDR signaling, orchestrates TDP-43’s interaction with CDK6 mRNA that leads to its 
controlled decay [96].
2.2 Stress granules
Stress granule (SG) assembly is a dynamic, reversible process that promotes cell 
survival when stress factors are present. Membraneless SG organelles vary in their 
morphology and building composition in a cell type-specific manner [97, 98]. As 
long as the assembly/disassembly ratio is maintained in healthy cells, SGs act as the 
emergency store house for certain classes of RNA and protein molecules to protect 
Figure 2. 
TDP-43 proteinopathy causes RNA processing defects. TDP-43 being a major functional subunit of spliceosomal 
complex regulates the RNA maturation processes of hundreds of target genes. Many of which are directly 
associated with amyotrophic lateral sclerosis (ALS) and FTD. TDP-43, through its RRM domains, binds 
mainly to intronic and 3ʹ UTR-located UG-repeat sequences of pre-mRNA to modulate their splicing events. 
In healthy condition, TDP-43 strongly promotes normal splicing events and inhibits disease-causing aberrant 
alternative splicing. However, ALS/FTD-TDP-43 pathology induces aberrant splicing several folds higher 
than normal splicing leading to mRNA dysregulation-associated proteinopathies in motor neurons and 
glia. Moreover, exposure to various environmental toxins like heavy metals (Lead, iron, zinc), pesticides 
(organochloride compounds), and food toxins (BMAA) could cause pathogenic alterations in TDP-43 leading 
to its mislocalization and dysregulation of its splicing activity as a result causing sporadic ALS.
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them from the various stress stimuli (Figure 3). However, altered SG assembly pro-
cesses are associated with a number of human diseases, including neurodegenera-
tive disorders and dementia [99]. Recent discoveries indicate SGs are critical players 
in modulating signal circuits determining cell death versus survival in response to 
stress exposure.
Emerging evidence suggests that TDP-43, but not FUS, regulates SG dynam-
ics and secondary polymerization of TIA-1, which is essential for SG assembly 
(Figure 3) [100]. TIA-1 is an RNA-binding protein and classical SG marker and has 
more recently been considered as a candidate gene for ALS and ALS/FTD due to 
its rare heterozygous mutations (P362L and E384K) in the conserved amino acid 
residues within its low complexity domain [101]. TDP-43 increases its association 
with TIA-1 in a time-dependent manner in response to the osmotic and oxidative 
stressor, Sorbitol, in primary glial cells or other stressor-induced SGs in primary 
cortical neurons and astrocytes [102]. Studies have also shown aging as a crucial 
modulator of SG dynamics in neurodegenerative conditions. Notably, wild-type 
and ALS-linked pathogenic TDP-43 mutants show distinct patterns of stress forma-
tion rates and morphology. Mutant TDP-43 exhibits faster stress granule incorpo-
ration along with rapid increases in granule-size, while wild-type TDP-43 forms 
increasing numbers of granules with consistent size over time [99]. Apart from 
the TIA-1 aggregation regulation, TDP-43 also controls the mRNA level of G3BP1, 
an essential SG initiation factor. The loss of functional TDP-43 or pathogenic 
TDP-43-mediated G3BP1 mRNA depletion perturbs the interaction between SG 
components and processing bodies, leading to impaired storage of polyadenylated 
mRNAs [103]. However, different TDP-43 ALS-mutant variants exhibit differential 
regulation mechanisms. For instance, TDP-43 D169G does not affect SG formation 
mechanism, but R361S and A382T variants show loss-of-function phenotypes with 
Figure 3. 
TDP-43 is a critical component of stress granule. Stress granule formation, in normal condition, is a very 
important cellular defense mechanism to overcome stress responses. Stress granule assembly and disassembly is 
a reversible process in healthy cells. It’s a membraneless structure consisting of stress granule marker proteins 
TIA-1, G3BP-1, and TDP-43 as the major structural component. Given that ALS-/FTD-associated TDP-43 
pathology induces aberrant cytosolic sequestration of toxic TDP-43, it impairs the reversible nature of stress 
granule formation mechanism, thereby inducing the seeding mechanism for protein aggregation.
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respect to SG dynamics [104, 105]. Interestingly, chronic TDP-43 liquid-liquid 
phase separation (LLPS) has been observed in neuronal cells and ALS-iPSc-derived 
motor neurons, even with only a transient stress induction from sonicated amyloid 
fibrils or arsenite. Early stage LLPS TDP-43 droplets are formed in the nucleus 
independent of conventional SG mechanisms. Cytosolic TDP-43 droplets formed 
by transient stress induction gradually incorporate importin-α and Nup62, leading 
to the mislocalization of nuclear pore complex proteins Nup107, Ran, and RanGap1. 
This situation inhibits nucleo-cytoplasmic shuttling and clearance of toxic TDP-43 
and results in neuronal cell death [106]. Hans et al. have shown that TDP-43 hyper-
ubiquitylation-mediated insolubility could happen by multiple distinct mechanisms 
independent of its translocation to cytosolic SGs [107]. This study shows neither 
endoplasmic reticulum kinase inhibitors nor translation blockers could prevent 
TDP-43 ubiquitylation. Moreover, the sorbitol-induced stress response involves 
impaired TDP-43 splicing activity, whereas sodium arsenite-induced SG forma-
tion occurs through oxidative stress, which can be quenched by the treatment with 
antioxidant like N-acetylcysteine. High-content screening of inhibitors for blocking 
pathogenic TDP-43 accumulation in SGs from ALS patient-derived iPSc-motor 
neurons has identified planar aromatic moieties with DNA intercalation properties 
as the potent small molecule therapy for ALS/FTD-TDP-43 pathology [108]. In this 
context, it is important to mention that TDP-43 aggregates/inclusions do not com-
pletely overlap with TDP-43 associated SGs, rather a subpopulation of those TDP-
43 aggregates enter into SGs, and ALS-pathology-linked TDP-43 inclusion bodies 
are devoid of SGs. Notably, SGs indirectly exhibit positive feedback regulation of 
TDP-43 aggregation by disrupting HDAC6-mediated pathogenic TDP-43 clearance 
from ALS neurons and thereby accelerating TDP-43’s cytosolic aggregation [109].
2.3 Novel roles of GTPases: Rab11 and RGNEF in neurodegeneration
A common feature in a number of neurodegenerative diseases, including ALS, 
Alzheimer’s, and Parkinson’s disease, is the impaired clearance and recycling of 
damaged and aggregated proteins from cells. Moreover, perturbation of physiologi-
cal vesicle trafficking systems affects several vital mechanisms in the cells, such as 
efficient nutrient absorption, failure of cell-to-cell communication, the immune 
response, and loss of synaptic transmission [110, 111]. Rab-GTPases, first discov-
ered in brain tissue, belong to the major subset of the Ras superfamily [112]. In 
neurons, Rab-GTPases primarily orchestrate vesicle sorting and trafficking between 
target membranes through their interactions with effector proteins (coat proteins, 
kinesins, and dyneins), in addition to tethering and SNARE complexes [113, 114]. 
Among the Rab-GTPases, Rab11 plays critical roles in trafficking, sorting, and 
recycling endosomal vesicles around the perinuclear region. Rab11 is transported 
to the cellular periphery via recycling vesicles traveling along the microtubules and 
directly regulates vesicular exocytosis at the plasma membrane (Figure 4) [115, 116]. 
Furthermore, Rab11 has been identified as the master regulator for the transport of 
neurotrophin receptors and β-integrin via axonal junctions in dorsal root ganglion 
neurons and is critical for their maturation, functionality, and survival [117]. Rab11 
participates in different cell survival pathways in neurodegenerative diseases in 
response prion/prion-like protein toxicity. In the ALS-TDP-43 Drosophila model, 
TDP-43 toxicity reduces levels of the synaptic growth promoting bone morphoge-
netic protein (BMP) at the neuromuscular junction and increases BMP receptors in 
recycling endosomes and at the neuromuscular junction. This pathogenic condition 
leads to larval crawling defects in ALS fruit flies, which are rescued by the overex-
pression of Rab11 [118]. Schwenk et al. has shown that TDP-43 regulates the number 
of Rab11-positive recycling endosomes in dendrites (Figure 4) [119]. These recycling 
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defects in turn affect transferrin recycling in neurons and its decrease in cerebrospi-
nal fluid of patients. In Drosophila, a Rab11 mutation induces JNK and MAPK/ERK 
signaling activation and apoptosis, resulting in defective eye and wing phenotypes 
[120, 121]. TDP-43 can be phosphorylated at threonine 153 and tyrosine 155 by MEK 
kinase, a central player in MAPK/ERK signaling pathway, in response to heat shock 
[122]. However, this unique phospho-TDP-43 variant is not involved in aggregate 
formation but is instead recruited to nucleoli for processing nucleolar-associated 
RNA. Further supporting the Drosophila model results, we have observed that 
sporadic ALS-TDP-43 mutations induce the loss of Rab11 in patients’ brain and spinal 
cord compared to age-matched control samples [123]. In contrast to MAPK/ERK and 
Akt signaling pathways operating in parallel to activate mTORC signaling [124], we 
have shown that Akt and ERK signaling pathways work in a competitive manner to 
determine the cell fate. Moreover, in Parkinson’s disease, Rab11 co-localizes with toxic 
α-synuclein inclusion bodies in dopaminergic neurons, and overexpression of Rab11 
prevents the affected neurons from degeneration and rescues behavioral deficits 
[125]. In Huntington’s disease, Rab11 overexpression restores synaptic dysfunction 
and prevents glutamate-induced cell death in neurons [126, 127]. Rab11 has also been 
found to co-localize with Rab7 and C9orf72 in postmortem ALS brain samples and 
primary cortical neurons exhibiting C9orf72-induced disrupted vesicular trafficking 
system in ALS [128]. These findings suggest a broader impact of TDP-43 mutation-
induced Rab11 dysfunction on cellular function and survival signaling cascades.
Apart from the Rab-GTPases of Ras superfamily, small RhoA GTPases also regu-
late broad spectrum of cellular mechanisms including cell-to-cell communication, 
migration, and proliferation. Given that the mode of GTPase functionality relies on 
the rate of GTP to GDP turn over and vice versa, dysregulation of guanine nucleo-
tide exchange factor (GNEF) that is responsible for such turnover has been linked 
to a number of diseases including neurodegeneration. Among this class of proteins 
with enzymatic activity, Rho GNEF (RGNEF/p190) is directly associated with neu-
rodegenerative disease like ALS, where it not only regulates the function of GTPases 
Figure 4. 
TDP-43 modulates synaptic vesicle trafficking. Synaptic vesicle trafficking is a crucial mechanism for 
transporting macromolecules and neurotransmitters across the neuronal axon junctions. Defect in this 
mechanism may lead to accumulation of toxic waste products in the cells and activation of neurodegenerative 
conditions. Ras-GTPases like Rab11 plays a critical role in endosomal vesicle trafficking, sorting, and recycling. 
A study with sporadic ALS patients’ brain and spinal cord samples show loss of Rab11 could be closely linked 
to TDP-43 proteinopathies in ALS and FTD. Loss of Rab11 affects the cargo load capacity and the size of the 
vesicles as well. This condition in turn activates JNK and MAPK/ERK signaling cascades leading to neuronal 
apoptosis.
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for stress survival [129] but also acts as the RNA-binding protein to modulate the 
stability of the crucial low molecular weight cytoskeleton protein neurofilament’s 
mRNA by binding to its 3′ untranslated region [130]. Emerging studies on GNEF’s 
involvement in ALS has revealed that RGNEF co-exists with TDP-43 and FUS in the 
neuronal cytoplasmic inclusion bodies in spinal motor neurons indicating a cross 
talk of protein aggregation and dysregulated cell signaling pathways in the ALS 
pathogenesis [131]. Micronuclei structures, containing small DNA fragments with 
clustered DSBs and surrounded by one lipid layer, are a strong hallmark of cellular 
metabolic stress, exposure to genotoxic agents, and genomic instability leading to 
apoptosis [132–134]. Notably, micronuclei have been observed in the ALS patient 
brain and spinal cord tissue samples. Studies have shown that TDP-43 interacts with 
RGNEF through its leucine-rich domain and forms co-aggregated structures [135]. 
Taken together, these findings further support the fact that genomic instability is 
one of the major outcomes in ALS-TDP-43 pathology leading to neuronal death.
3. DNA binding and role in DNA transactions
TDP-43 was first identified and characterized as the transcriptional regulator of 
HIV-1 gene expression by binding to long terminal repeat TAR DNA motifs [136]. In 
contrast, a separate study found that when exposed to HIV-1 infection, HIV-1 viral 
production could occur in T cells and macrophages, even in the absence of TDP-43 
protein [137]. As an RNA-/DNA-binding protein, TDP-43 also interacts with spe-
cific TG and non-TG repeat containing DNA sequences through its RRM domains, 
with each domain having specific interaction affinities and DNA conformation 
requirements [138]. TDP-43 has been found to regulate the cyclin-dependent kinase 
6 (CDK6) transcript and protein levels through its binding to the highly conserved 
long-stretch of GT repeats in CDK6 gene sequence. This binding leads to CDK6 
upregulation and thereby increases phosphorylation of retinoblastoma proteins pRb 
and pRb2/p130 [139]. TDP-43 also acts as the transcriptional repressor and/or insu-
lation regulator for the spatiotemporal regulation of the ACRV1 (SP-10) gene [140, 
141]. TDP-43 binds to two GTGTGT motifs in the promoter core region through 
its N-terminal RRM1 domain during spermatogenesis. In vivo studies reveal that, 
unlike the wild-type variant, mutations in the GTGTGT motifs in the −186/+28 
promoter region leads to premature reporter gene expression in the meiotic sper-
matocytes [142]. Previously, TDP-43 has been shown to bind both double-stranded 
DNA as well as single-stranded DNA, with a higher affinity toward single-stranded 
DNA through binding its RRM1 domain [143, 144]. Qin et al. reported that TDP-
43’s N-terminal domain is indispensable for its physiological and proteinopathy 
functions and showed that the N-terminus maintains a highly ordered structure 
that equilibrates the C-terminal disordered structure by acquiring a novel ubiq-
uitin-like fold that directly binds single-strand DNA [145]. More recently, we also 
documented in vitro studies on TDP-43’s affinity for binding free double-stranded 
DNA ends, instead of binding a partially or completely blocked terminus [146].
4. TDP-43 in DNA damage response (DDR) and repair
Induction of DNA damage and dysregulated damage response are critical factors 
for neuronal death in ALS and other neurodegenerative diseases [147, 148]. Studies 
also suggest endogenous DNA breaks, including DSBs, are routinely generated and 
repaired in healthy neurons and are essential for the regulation of neuronal gene 
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expression [149, 150]. Besides the transcriptional regulation by RRM domains of 
TDP-43, no other DNA interactions have been reported for TDP-43. Based on an 
interactome study targeting TDP-43 in human cells, Freibaum et al. identified 
the DNA repair protein, Ku70, as one of the interacting partners of TDP-43 [151]. 
Furthermore, we found that TDP-43’s interaction with Ku70 was modulated by DNA 
damage induction in neuronal cells. Notably, TDP-43 showed pathway-specific roles 
in DNA DSB repair via direct interaction with the classical nonhomologous end join-
ing (NHEJ) factors XRCC4 and DNA Ligase 4 (LIG4) complex, but not with single-
strand break repair factors XRCC1 and DNA Ligase 3 (LIG3) complex. Further 
experimental studies revealed TDP-43’s interaction with a number of NHEJ pro-
teins, including DNA-PKcs, 53BP1, polymerase lambda, XRCC4-like factor (XLF), 
and the DNA damage response (DDR) factors phosphorylated ATM and histone 
H2AX (γH2AX). Interestingly, TDP-43 depletion in neurons elicited hyperactivation 
of DDR signaling without affecting the recruitment of activated DDR proteins to 
genome damage sites and inhibited the docking, but not assembly, of DNA ligation 
complex factors (XRCC4, LIG4, and XLF) at the break sites. This suggests that 
TDP-43 has a crucial role in maintenance of genomic integrity by efficiently com-
pleting the rate-limiting DSB sealing step (Figure 5). Consistent with these results, 
neuronal cells with TDP-43 downregulation exhibited delayed DSB repair kinetics 
and a higher population of apoptotic cells due to the persistent accumulation of 
unrepaired DSBs than controls. In a correlative study of postmortem human spo-
radic ALS brain and cervical spinal cord samples, we determined that samples with 
extensive TDP-43 aggregation and/or fragmentation had greater staining for DSB 
markers (γH2AX and TUNEL) than their age-matched controls [146].
Figure 5. 
TDP-43’s scaffolding role in NHEJ repair mechanism of nuclear genome. In response to DNA damage 
induction, TDP-43 gets recruited at the DSB sites and participates in relaying DDR signaling through 
interaction with p-ATM (Serine1981), p-histone H2AX (Serine139), p-53BP1 (Serine1778), and Ku70/80 
heterodimer. More importantly, TDP-43 regulates the most rate-limiting step of the DNA DSB repair 
pathway—DNA DSB end ligation, through its interaction with DNA ligation complex XRCC4-ligase 4 at 
the break sites. However, pathogenic mutations in TDP-43 related to ALS and FTD cause enhanced cytosolic 
mislocalization of TDP-43, thereby inhibiting the DNA damage-induced translocation of XRCC4-ligase 4 
complex from cytosol to nucleus. Either of TDP-43 loss-of-function or ligation complex translocation inhibition 
causes DNA DSB repair impairment leading to nuclear genome instability in ALS/FTD motor neurons.
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4.1 Mutant TDP-43 and defective DSB repair in neurons
Efficient sealing of DNA DSBs, which are the most lethal form of DNA dam-
age, is critical for maintaining genome integrity and fidelity. In the majority of the 
SALS cases, the total amount of TDP-43 does not change significantly, but a sig-
nificant proportion of the protein mislocalizes to the cytosol and causes ALS/FTD 
pathophysiology similar to disease-linked mutant TDP-43. We recently linked the 
TDP-43 Q331K mutation with genome instability and DSB repair defects. In studies 
with conditionally expressed TDP-43 Q331K mutant, cultured neurons exhibited a 
strong nuclear clearance phenotype and a higher amount of DNA damage at basal 
level without the effect of any external DNA damaging agents than control cells. 
Further investigations showed that TDP-43 Q331K trapped XRCC4 and LIG4 in the 
cytosol and inhibited their translocation to the nucleus in response to DNA damage 
induction. These findings suggest that TDP-43 is not only involved in the recruit-
ment of the DNA ligation complex at genomic break sites but also regulates the 
damage-dependent nuclear translocation of DNA repair proteins (Figure 5). These 
impaired TDP-43 functions in the disease condition leading to genomic instability 
and neurodegeneration [22].
5.  A double whammy of DNA damage induction and defects in their 
repair in TDP-43-ALS
We and others have observed that the most salient hallmarks of ALS/FTD-
TDP-43 pathology, the protein aggregation and inclusion body formation in 
the cytosol, increase oxidative stress in affected neurons [22, 48, 152, 153]. 
4-hydroxynonenal (HNE) increases as an oxidative stress indicator in sporadic ALS 
patients’ brain, spinal cord, and serum. HNE induces oxidative damage to a broad 
range of cysteine-containing proteins, including TDP-43, through cysteine oxida-
tion. Oxidized TDP-43 mislocalizes from the nucleus to form insoluble cytosolic 
aggregates in ALS [154]. Such nuclear clearance and cytosolic increase may cause a 
gain-of-toxicity, leading to aberrant mRNA processing, which in turn exerts a direct 
DNA destabilization through impaired DSB repair and an indirect repair inhibition 
by negatively regulating mRNA splicing of DNA repair proteins. Furthermore, 
the unrepaired DNA DSBs leads to persistent DDR signaling activation through an 
ATM-mediated signaling cascade that promotes neuroinflammation. This inflam-
matory response may induce oxidative genome damage and enhanced TDP-43’s 
nuclear clearance, exacerbating the ALS/FTD conditions in a feed forward pattern. 
Moreover, dysregulation of metal homeostasis has been observed in ALS patients’ 
brain/spinal cord tissues. In the presence of cellular oxidative stress, zinc induces 
TDP-43’s mislocalization and cytoplasmic inclusions [155, 156]. Given that zinc is 
a crucial metal co-activator for several transcription factors, trapping of zinc in 
TDP-43 aggregates could globally affect gene activation patterns, including those 
for DNA repair and response-associated factors, leading to genomic instability.
6. Conclusions: TDP-43-ALS, a case for DNA repair-targeted therapy?
Emerging studies from our laboratory and other groups have shown that in 
addition to its RNA processing and miRNA biogenesis functions, TDP-43 acts as a 
key component of the NHEJ pathway for DSB repair in neurons, and its pathological 
clearance from the nucleus leads to the DSB repair defects seen in ALS and other 
TDP-43-linked neurodegenerative diseases. These newly discovered paradigms link 
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TDP-43 pathology to impaired DNA repair and suggest potential avenues for DNA 
repair-targeted therapies for TDP-43-ALS and related motor neuron diseases. Future 
studies should focus on a comprehensive delineation of the molecular mechanisms 
involved in order to develop efficiently targeted interventions. In addition, the impli-
cations of these defects in neuronal and glial functions in the CNS of TDP-43-ALS 
patients and the role of TDP-43 in maintaining genome integrity in non-neuronal 
brain cells, including glia and astrocytes, are important lines of investigation. By 
comparing the DNA repair role of TDP-43 in post-mitotic vs. cycling cells, we could 
learn important mechanistic insights on the selective vulnerability of neurons in ALS.
Recently, an increasing number of studies have demonstrated the role of RNA/
DNA-binding proteins in DNA repair. We previously documented the involve-
ment of hnRNP-U, a member of the hnRNP family, in oxidative damage repair 
in the human genome and its role as a molecular switch between DSB repair and 
oxidative damage repair when these complex damages occur in a clustered fashion 
[157, 158]. We also discovered that another RNA-/DNA-binding protein, fused in 
sarcoma/translocated in liposarcoma (FUS/TLS), linked to the ALS-FUS subtype, 
participates in break sealing during DNA SSB repair [10]. Because both TDP-43 and 
FUS influence the final DNA break/sealing step of repair, further investigations in 
DNA repair mechanisms are critical to developing clinically effective strategies for 
ameliorating the genome instability of ALS-TDP-43.
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